Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

DICERNA PHARMACEUTICALS, INC.

(DRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Sector Update: Health Care Stocks Still Narrowly Higher in Late Regular-Hours Trade

05/24/2021 | 03:54pm EDT


ę MT Newswires 2021
All news about DICERNA PHARMACEUTICALS, INC.
08/02DICERNA PHARMACEUTICALS : to Report Second Quarter 2021 Financial Results on Aug..
BU
07/30DICERNA PHARMACEUTICALS : Announces FDA Clearance of Investigational New Drug Ap..
AQ
07/29DICERNA PHARMACEUTICALS' : New Drug Application Targeting Alcohol Use Disorder G..
MT
07/29DICERNA PHARMACEUTICALS : Announces FDA Clearance of Investigational New Drug (I..
BU
07/29Dicerna Pharmaceuticals, Inc. Announces FDA Clearance of Investigational New ..
CI
07/29Dicerna Announces FDA Clearance of Investigational New Drug Application for D..
CI
07/23DICERNA PHARMACEUTICALS : Corporate Overview
PU
07/21SECTOR UPDATE : Health Care Stocks Mixed Ahead of Wednesday Close
MT
07/21SECTOR UPDATE : Health Care Stocks Mixed, Nearly Flat Wednesday
MT
07/21DICERNA PHARMACEUTICALS : Reports Positive Interim Data From Phase 1 Study of Be..
MT
More news
Financials (USD)
Sales 2021 245 M - -
Net income 2021 -75,2 M - -
Net cash 2021 524 M - -
P/E ratio 2021 -39,2x
Yield 2021 -
Capitalization 2 868 M 2 868 M -
EV / Sales 2021 9,56x
EV / Sales 2022 13,3x
Nbr of Employees 302
Free-Float 91,7%
Chart DICERNA PHARMACEUTICALS, INC.
Duration : Period :
Dicerna Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DICERNA PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Last Close Price 37,30 $
Average target price 42,00 $
Spread / Average Target 12,6%
EPS Revisions
Managers and Directors
Douglas M. Fambrough President, Chief Executive Officer & Director
Douglas W. Pagßn Chief Financial Officer
J. Kevin Buchi Chairman
Bob D. Brown Chief Scientific Officer
Shreeram Aradhye Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
DICERNA PHARMACEUTICALS, INC.69.31%2 868
GILEAD SCIENCES, INC.19.86%87 579
BIONTECH SE408.39%84 970
WUXI APPTEC CO., LTD.41.52%71 929
REGENERON PHARMACEUTICALS21.40%60 737
VERTEX PHARMACEUTICALS-15.55%51 899